Biotech Sector Sees Major Offerings Led by Oruka and Intellia

Key Facts

1Intellia Therapeutics has commenced an underwritten public offering of $150 million of shares of its common stock.

2Intellia intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered.

The biotechnology sector is witnessing a surge in capital raising, highlighted by Oruka Therapeutics upsizing its public offering to approximately $700.4 million at $72.50 per share. In a parallel development, Intellia Therapeutics finalized its public offering pricing at $10.75 per share for 16,744,187 shares of common stock. Gross proceeds for Intellia are now expected to reach approximately $180 million, exceeding the initial $150 million estimate due to strong demand. Additionally, Intellia granted underwriters a 30-day option to purchase up to 2,511,628 additional shares. These concurrent capital raises underscore a broader trend of biotech firms fortifying balance sheets to fund expensive clinical pipelines. Market participants are closely monitoring how this influx of liquidity will accelerate research in CRISPR-based therapies and genomic medicine.

6 months ago

Version History

Version 36 months ago

What changed: Updated with finalized pricing details for Intellia Therapeutics, reflecting a higher capital raise of $180 million compared to the initial $150 million estimate.

Version 26 months ago

What changed: Updated Oruka's offering size to $700.4 million, confirmed the $72.50 share price, and included specific underwriter share options.

Version 16 months ago

What changed: Updated the story to include Oruka Therapeutics' significantly larger $500 million offering and the inclusion of pre-funded warrants.